No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 545 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of... February 2, 2022 Scientists Find Genetic Changes Linked to Cancer in Children March 4, 2025 Woman Died From Stage IV Breast Cancer After Doctor Misread Her... July 1, 2020 Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... September 3, 2025 Load more HOT NEWS Coronavirus y COVID-19: Qué deben saber las personas con cáncer Por qué la Reunión Anual de la American Society of Clinical... Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... Navigating Life During and After Cancer As a Young Adult: A...
